The raised guidance and strong beat across all segments signal sustained momentum. Watch for closing of the Option Care Health investment and further capital deployment updates on the earnings call.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $1,072.00entry
- T+1 · 11d ago −1.04%α −1.35% · $1,060.84
- T+5 · 5d ago +0.47%α −2.82% · $1,077.05
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
McKesson reported fiscal Q2 2027 revenue of $111.0B (+8% YoY) and adjusted EPS of $11.68 (+18% YoY), beating the consensus estimate of $10.75. The company raised its full-year adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00, citing strong operational performance across segments.
Key Financial Metrics
Key Facts
- Q2 FY2027 revenue $110.96B, +8% YoY vs $103.15B
- Q2 GAAP diluted EPS $10.44 vs $8.92 YoY, +17%
- Q2 adjusted diluted EPS $11.68 vs $9.86 YoY, +18%
- Adjusted EPS beat consensus of $10.75 by 8.7%
- Full-year adjusted EPS guidance raised to $45.60-$46.40 from $44.20-$45.00
- North American Pharmaceutical segment adjusted operating profit +22% YoY
- Oncology Multispecialty segment revenue +24% YoY
- Generated $3.1B operating cash flow and $2.9B free cash flow in Q2
- Returned $3.6B to shareholders YTD via buybacks and dividends
- Signed agreement to extend CVS Health distribution partnership through 2032
- Completed acquisition of Precision Medicine Group on Nov 2, 2026
- Signed $1.4B deal for ~49% minority stake in Option Care Health
Financial Impact
Q2 adjusted EPS of $11.68 beat consensus of $10.75 by $0.93 (+8.7%); full-year guidance raised by $1.40 at midpoint to $46.00
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| North American Pharmaceutical | $91.4B | +6.0% |
| Oncology Multispecialty | $15.0B | +24.0% |
| Prescription Technology Solutions | $1.5B | +10.0% |
| Medical-Surgical Solutions | $3.1B | +5.0% |
Risk Factors
- Medical-Surgical Solutions adjusted operating profit declined 10% YoY due to ambulatory care mix
- Planned separation of Medical-Surgical Solutions and Option Care Health deal subject to regulatory approvals
- Opioid litigation liabilities remain at $4.6B on the balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000927653-26-000279 |
| Document: mck-20261104.htm | 0000927653-26-000279 |
| Document: 0000927653-26-000279-index-headers.html | 0000927653-26-000279 |
| Document: 0000927653-26-000279-index.html | 0000927653-26-000279 |
| Document: 0000927653-26-000279.txt | 0000927653-26-000279 |
| 8-K Data (Synthetic) | 0000927653-26-000279 |
Track record
26 reports on MCK
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +22.92% at T+60 after the Apr 1, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
- Oct 30, 202617d ago 25-NSE Neutral 1/10 Entry $994.58 to $1,060.84 Now $1,102.81 +10.88% ▲ +6.66% +9.37% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,102.81 +14.81% ▲ +11.34% +12.05% vs SPY
- Oct 27, 202621d ago GOVT-CONTRACT Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,102.81 +14.81% ▲ +11.34% +12.05% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $955.76 to $1,010.43 Now $1,102.81 +15.39% ▲ +5.72% +7.21% vs SPY
- Oct 6, 20265w ago 8-K Bullish 6/10 Entry $921.67 to $961.88 Now $1,102.81 +19.65% ▲ +4.36% +4.50% vs SPY
- Sep 1, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $924.78 to $880.86 Now $1,102.81 +19.25% ▼ −4.75% −3.79% vs SPY
- Aug 28, 202611w ago 8-K Neutral 4/10 Entry $885.32 to $896.29 Now $1,102.81 +24.57% ▲ +1.24% +1.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers